Cynthia Robinson, in Greensboro, AL - Licensed Practical Nurse

Cynthia Robinson, is a Licensed Practical Nurse based in Greensboro, Alabama. Cynthia Robinson is licensed to practice in Alabama (license number 2-048675) and her current practice location is 508 Green St, Greensboro, Alabama. She can be reached at her office (for appointments etc.) via phone at (334) 624-3024.

NPI number for Cynthia Robinson is 1801051271 and her current mailing address is 1618 Bell St, Demopolis, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1801051271.

Contact Information

	Cynthia Robinson,
	508 Green St, Greensboro, AL 36744-2316
	(334) 624-3024
	Not Available

Provider's Profile

Full Name	Cynthia Robinson
Gender	Female
Speciality	Licensed Practical Nurse
Location	508 Green St, Greensboro, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1801051271
Provider Enumeration Date: 07/24/2008
Last Update Date: 07/24/2008

Medical Identifiers

Medical identifiers for Cynthia Robinson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1801051271	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164W00000X	Licensed Practical Nurse	2-048675 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Cynthia Robinson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Cynthia Robinson, 1618 Bell St, Demopolis, AL 36732-3810 Ph: (334) 289-0633	Cynthia Robinson, 508 Green St, Greensboro, AL 36744-2316 Ph: (334) 624-3024

News Archive

Women diagnosed with precancerous cervical intraepithelial neoplasia at risk for cervical cancer

Long-term risks of invasive cancer and recurrence of severe cervical intraepithelial neoplasia (CIN) are higher among women previously treated for CIN, compared with those with no CIN diagnosis, according to data from a large, retrospective cohort study published in the May 12 online issue of the Journal of the National Cancer Institute

Top-line results from Amgen's Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

A possible H5N1 vaccine

A vaccine against the most common and deadliest strain of avian flu, H5N1, has been engineered and tested by researchers at the University of Pittsburgh's Center for Vaccine Research and Novavax Inc.

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite Vision Incorporated and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.

Ecstasy may cause long-term brain damage

Ecstasy - the illegal "rave" drug that produces feelings of euphoria and emotional warmth - has been in the news recently as a potential therapeutic. Clinical trials are testing Ecstasy in the treatment of post-traumatic stress disorder.

Cynthia Robinson, - Licensed Practical Nurse in Greensboro, AL